Jennison Associates
ALT icon

Jennison Associates’s Altimmune ALT Stock Holding History

Jennison Associates’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-928,813
Closed -$15.3M – 587
2022
Q4 		$15.3M Buy
928,813
+747,283
+412% +$8.39M 0.02% 359
2022
Q3 		$2.32M Buy
181,530
+72,066
+66% +$1.06M ﹤0.01% 451
2022
Q2 		$1.28M Buy
+109,464
New +$675K ﹤0.01% 494

Other funds holding ALT

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Jennison Associates's ALT Position: Q1 2023 in Review

Jennison Associates sold out of Altimmune (ALT) in Q1 2023, closing a stake of 928,813 shares — an estimated $15.3M sold.

Jennison Associates first reported a position in ALT in Q2 2022 and held it in 3 quarters. The position peaked at $15.3M in Q4 2022. 132 funds tracked by Wall St. Rank hold ALT as of Q1 2023.

  • Jennison Associates reported no remaining Altimmune position as of Q1 2023 after selling out during the quarter.
  • Jennison Associates sold 928,813 Altimmune shares in Q1 2023, an estimated $15.3M.
  • Jennison Associates first reported a position in Altimmune in Q2 2022 and held it in 3 quarters.
  • Jennison Associates's Altimmune position peaked at $15.3M in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Altimmune as of Q1 2023.

Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.